Table 1 Sociodemographic and clinical parameters of the patient cohort analysed
Patient characteristics | n (%) / mean (SD) n = 424 |
|---|---|
Female | 98 (23.1%) |
Age in years | 68.7 (9.1) |
Age at first symptom onset in years | 64.9 (10.3) |
Age at diagnosis in years | 66.8 (9.7) |
Duration since first symptoms in years | 3.7 (4.1) |
Disease duration in months | 2.0 (2.7) |
< 3 months | 124 (29.5%) |
3 to < 6 months | 39 (9.3%) |
More than 6 months | 258 (61.3%) |
Smoking status | |
Never | 161 (38.0%) |
Former stopped | 256 (60.4%) |
Current | 7 (1.7%) |
Number of comorbidities | |
None | 95 (22.4%) |
1 | 124 (29.3%) |
2 | 107 (25.2%) |
3 | 63 (14.9%) |
4+ | 35 (8.3%) |
NHYA | |
I | 28 (14.7%) |
II | 81 (42.6%) |
III | 76 (40.0%) |
IV | 5 (2.6%) |
Six-minute walk distance (m) | 287.7 (199.6) |
% FEV1 | 68.3 (17.4) |
% FVC | 36.1 (15.9) |
% DLCO | 75.9 (19.4) |
GAP index | 4.7 (1.4) |
Stage I | 72 (18.8%) |
Stage II | 203 (53.0%) |
Stage III | 108 (28.2%) |
Overall physician’s judgement of clinical course of IPF | |
Stable disease | 166 (39.2%) |
Slow progression | 123 (29.0%) |
Rapid progression | 31 (7.3%) |
No judgement possible | 104 (24.5%) |
SGRQ | 45.9 (19.7) |
SGRQ symptoms | 55.9 (21.0) |
SGRQ activity | 59.7 (23.6) |
SGRQ impacts | 34.8 (20.7) |
UCSD-SOBQ | 43.9 (28.8) |
EQ-5D VAS | 62.6 (18.5) |
WHO-5 | 14.8 (5.7) |